Interleukin Inhibitors Market Size
| Study Period | 2019 - 2029 |
| Base Year For Estimation | 2023 |
| CAGR | 12.50 % |
| Fastest Growing Market | North America |
| Largest Market | Asia Pacific |
| Market Concentration | Medium |
Major Players
*Disclaimer: Major Players sorted in no particular order |
Interleukin Inhibitors Market Analysis
The Interleukin Inhibitors Market is expected to register a CAGR of 12.5% during the forecast period.
The pandemic had an adverse effect on the studied market. However, the drug has the potential to provide therapeutic support in Covid treatment. According to a research study published in August 2020 with the title "The role of Interleukin 6 inhibitors in therapy of severe COVID-19," cytokine storm syndrome (CSS) is a serious complication of treating malignancies or inflammatory immune diseases, and it can also manifest during the progression of COVID-19. The pathophysiology of CSS is significantly influenced by interleukin-6 (IL-6). Numerous investigations that demonstrated that patients with severe COVID-19 had higher plasma concentrations of IL-6 corroborated the important role that IL-6 plays in the pathophysiology of the disease. Studies that sought to identify additional pertinent therapeutic targets for the treatment of CSS in patients with COVID-19 are necessary for the creation of customized immunomodulatory therapy, given the role of cytokines in pathogenesis. Thus, the market is expected to grow in the future.
The major factors driving the growth of the market include the increasing global prevalence of autoimmune disorders and rising geriatric population and technological advancements in the development of novel interleukin inhibitors. According to the Yondala Smith article titled 'Psoriasis Epidemiology' updated in March 2021, Psoriasis affects approximately 125 million people globally, which is about 2.2% of the worldwide population. The prevalence varies in different areas of the world. However, higher rates are reported in developed countries accounting for 4.6% of the population. The same source also reported that the incidence of psoriasis is most common between the ages of 15 and 25, however, it may affect individuals of any age. Psoriatic arthritis typically develops ten years or more after the initial diagnosis of psoriasis, between the ages of 30 and 50. Such a high burden of diseases is boosting the growth of the market. Furthermore, an article in the Journal of the European Academy of Dermatology and Venerology titled 'Prevalence of Most Common Skin Diseases in Europe: A Population-based Study,' published in March 2022, reported that in France, the prevalence of psoriasis is 3.92%, which accounts for more than 16 million people. Also, as per the 2021 International Foundation For Gastrointestinal Disorders (IFFGD), 10 to 15% of the population is affected by irritable bowel syndrome worldwide, including 25 to 45 million people afflicted with the disease in the United States. As Crohn's disease is a type of irritable bowel syndrome, its increasing burden also boosts the growth of the market. Additionally, according to the October 2021 update of the World Health Organization, the percentage of people aged more than 60 years in the global population is expected to increase from 12% in 2015 to 22% by 2050, of which about 80% of the older people in 2050 are anticipated to be living in the low-and middle-income countries. Such an increasing burden on the geriatric population is expected to boost the growth of the market over the forecast period. Product launches are another factor in market growth. For instance, in July 2020, UCB announced positive results from the Phase 3b BE RADIANT study for the use of the IL-17A and IL-17F inhibitor bimekizumab in the treatment of adult patients with moderate-to-severe plaque psoriasis. Similarly, in March 2020, Sanofi and Regeneron launched trials for evaluating the efficacy of Kevzara which is an interleukin-6 inhibitor (IL-6) for the treatment of severely ill COVID-19 patients.Thus, owing to the above-mentioned factors it is expected to drive market growth over the forecast period.
However, the high cost of the treatment and stringent regulatory policies are expected to hinder market growth.
Interleukin Inhibitors Market Trends
This section covers the major market trends shaping the Interleukin Inhibitors market according to our research experts:
Asthma Segment is Expected to Hold a Significant Market Share Over the Forecast Period.
Asthma is one of the major non-communicable diseases. It is a chronic disease of the lung air passages, which inflames and narrows them. Asthma restricts airways and can cause nighttime coughing, wheezing, and breathlessness, potentially interfering with the ability to get a good night's sleep. According to the World Population Ageing Highlight 2020 report by the United Nations, the global geriatric population is increasing rapidly worldwide. In 2020, about 727 million people aged 65 years or older were living across the world, about 9.3% of the global population. The same report projected that the population of people aged 65 years or more is expected to be about 1.5 billion by 2050, which will be about 16% of the global population. Thus, the growing aging population is expected to significantly impact the growth of the market studied during the forecast period. According to the Canadian Pediatric Society in November 2021, entitled 'Managing an acute asthma exacerbation in children,' asthma prevalence in Canada has been estimated to be 10% overall. Still, it can reach 20% of children and adolescents, including their indigenous peers. Exacerbations of asthma are common reasons children visit the emergency room (ED), be admitted to the hospital, and miss school. More than 50% of ED visits from children with asthma are from this age group. Moreover, one child died in Alberta for every 25,000 emergency department visits or about 10% of pediatric ED visits. According to the study titled 'Risk factors of asthma in the Asian population: a systematic review and meta-analysis,' published in the Journal of Physiological Anthropology in December 2021, the Asia-Pacific region saw an increase in the prevalence of asthma-related symptoms over the past 12 months. Further research into the disease-related risk factors unique to the Asia-Pacific region is expected to offer opportunities to create more effective preventative, prognostic, and therapeutic strategies for managing asthma disease, given the region's rising trend in asthma prevalence. Thus, the abovementioned factors are expected to increase market growth.
North America Region is Expected to Hold a Major Market Share Over the Forecast Period
In the North America region, the United States is expected to hold a significant market share due to the presence of major market players, increasing research and development activities in the development of novel products, proactive government initiatives, and an increase in healthcare expenditure. Asthma is a primary noncommunicable disease (NCD) affecting children and adults and is the most common chronic disease among children. Also, according to the Asthma and Allergy Foundation of America (AAFA), in April 2022, roughly 1 in 13 Americans had asthma, which is about 25 million people. As per the abovementioned source, about 5.1 million American children under 18 have asthma. The same source stated that asthma is more common in female adults than in male adults. Around 9.8% of female adults have asthma, compared to 6.1% of male adults. Thus, patients with respiratory illnesses often require portable oxygen concentrators for treatment purposes, creating opportunities for ventilators and boosting market growth. Moreover, the United States is under pressure to overcome the respiratory disease burden and its economic impact. For instance, in the article 'Does Chronic Obstructive Pulmonary Disease Affect Workers' Health?' published in July 2021, researchers estimated that the annual direct costs of COPD in the United States are USD 18 billion.
Thus, the abovementioned factors are expected to increase market growth.
Interleukin Inhibitors Industry Overview
The Interleukin Inhibitors Market is moderately consolidated . Some market players are focusing on implementing strategies such as partnerships, distribution agreements, and regional expansion to increase their revenue share. Some of the market players include Johnson and Johnson, Novartis AG, AbbVie Inc, Eli Lilly and Company, AstraZeneca Plc, Sun Pharmaceutical Industries Limited, F. Hoffmann-La Roche Ltd, GlaxoSmithKline plc, Teva Pharmaceuticals Industries, Ltd and others.
Interleukin Inhibitors Market Leaders
-
AbbVie, Inc
-
Johnson and Johnson
-
Novartis AG
-
Eli Lilly and Company
-
GlaxoSmithKline Plc
*Disclaimer: Major Players sorted in no particular order
Interleukin Inhibitors Market News
- In July 2022, SKYRIZI (risankizumab-rzaa) received Food and Drug Administration (FDA) approval as the first interleukin-23 (IL-23) for the treatment of moderately to severely active Crohn's disease in adults.
- In July 2021, Ortho Clinical Diagnostics, one of the world's largest pure-play in vitro diagnostics companies, launched VITROS Immunodiagnostic Products IL-6 Reagent Pack.
Interleukin Inhibitors Market Report - Table of Contents
1. INTRODUCTION
- 1.1 Study Assumptions and Market Definition
- 1.2 Scope of the Study
2. RESEARCH METHODOLOGY
3. EXECUTIVE SUMMARY
4. MARKET DYNAMICS
- 4.1 Market Overview
-
4.2 Market Drivers
- 4.2.1 Increasing Global Prevalence of Autoimmune Disorders and Rising Geriatric Popuation
- 4.2.2 Technological Advancements
-
4.3 Market Restraints
- 4.3.1 High Cost of the Treatment
- 4.3.2 Stringent Regulatory Policies
-
4.4 Porter's Five Force Analysis
- 4.4.1 Threat of New Entrants
- 4.4.2 Bargaining Power of Buyers/Consumers
- 4.4.3 Bargaining Power of Suppliers
- 4.4.4 Threat of Substitute Products
- 4.4.5 Intensity of Competitive Rivalry
5. MARKET SEGMENTATION (Market Size by Value - USD million)
-
5.1 By Type
- 5.1.1 IL-1
- 5.1.2 IL-5
- 5.1.3 IL-6
- 5.1.4 IL-17
- 5.1.5 IL-23
- 5.1.6 Other types
-
5.2 By Application
- 5.2.1 Psoriasis
- 5.2.2 Arthritis
- 5.2.3 Asthma
- 5.2.4 Inflammatory Bowel Disease (IBD)
- 5.2.5 Other Applications
-
5.3 Geography
- 5.3.1 North America
- 5.3.1.1 United States
- 5.3.1.2 Canada
- 5.3.1.3 Mexico
- 5.3.2 Europe
- 5.3.2.1 Germany
- 5.3.2.2 United Kingdom
- 5.3.2.3 France
- 5.3.2.4 Italy
- 5.3.2.5 Spain
- 5.3.2.6 Rest of Europe
- 5.3.3 Asia-Pacific
- 5.3.3.1 China
- 5.3.3.2 Japan
- 5.3.3.3 India
- 5.3.3.4 Australia
- 5.3.3.5 South Korea
- 5.3.3.6 Rest of Asia-Pacific
- 5.3.4 Middle-East and Africa
- 5.3.4.1 GCC
- 5.3.4.2 South Africa
- 5.3.4.3 Rest of Middle East and Africa
- 5.3.5 South America
- 5.3.5.1 Brazil
- 5.3.5.2 Argentina
- 5.3.5.3 Rest of South America
6. COMPETITIVE LANDSCAPE
-
6.1 Company Profiles
- 6.1.1 AbbVie, Inc
- 6.1.2 AstraZeneca Plc
- 6.1.3 Bausch Health
- 6.1.4 Eli Lilly and Company
- 6.1.5 F. Hoffmann-La Roche Ltd
- 6.1.6 GlaxoSmithKline Plc
- 6.1.7 Johnson and Johnson
- 6.1.8 Novartis AG
- 6.1.9 Regeneron Pharmaceuticals, Inc
- 6.1.10 Sun Pharmaceutical Industries Limited
- 6.1.11 Teva Pharmaceuticals Industries, Ltd
- *List Not Exhaustive
7. MARKET OPPORTUNITIES AND FUTURE TRENDS
** Subject To AvailablityInterleukin Inhibitors Industry Segmentation
As per the scope of the report, Interleukin inhibitors are immunosuppressive agents which inhibit the action of interleukins which are synthesized by monocytes, macrophages, lymphocytes and certain other cells. The Interleukin Inhibitors Market is Segmented by Type (IL-1, IL-5, IL-6, IL-17, IL-23, and Other Types), Application (Psoriasis, Arthritis, Asthma, Inflammatory Bowel Disease, and Other Applications), and Geography (North America, Europe, Asia-Pacific, Middle East and Africa, and South America). The market report also covers the estimated market sizes and trends for 17 different countries across major regions, globally. The report offers the value (in USD million) for the above segments.
| By Type | IL-1 | |
| IL-5 | ||
| IL-6 | ||
| IL-17 | ||
| IL-23 | ||
| Other types | ||
| By Application | Psoriasis | |
| Arthritis | ||
| Asthma | ||
| Inflammatory Bowel Disease (IBD) | ||
| Other Applications | ||
| Geography | North America | United States |
| Canada | ||
| Mexico | ||
| Geography | Europe | Germany |
| United Kingdom | ||
| France | ||
| Italy | ||
| Spain | ||
| Rest of Europe | ||
| Geography | Asia-Pacific | China |
| Japan | ||
| India | ||
| Australia | ||
| South Korea | ||
| Rest of Asia-Pacific | ||
| Geography | Middle-East and Africa | GCC |
| South Africa | ||
| Rest of Middle East and Africa | ||
| Geography | South America | Brazil |
| Argentina | ||
| Rest of South America |
Interleukin Inhibitors Market Research FAQs
What is the current Global Interleukin Inhibitors Market size?
The Global Interleukin Inhibitors Market is projected to register a CAGR of 12.5% during the forecast period (2024-2029)
Who are the key players in Global Interleukin Inhibitors Market?
AbbVie, Inc, Johnson and Johnson, Novartis AG, Eli Lilly and Company and GlaxoSmithKline Plc are the major companies operating in the Global Interleukin Inhibitors Market.
Which is the fastest growing region in Global Interleukin Inhibitors Market?
North America is estimated to grow at the highest CAGR over the forecast period (2024-2029).
Which region has the biggest share in Global Interleukin Inhibitors Market?
In 2024, the Asia Pacific accounts for the largest market share in Global Interleukin Inhibitors Market.
What years does this Global Interleukin Inhibitors Market cover?
The report covers the Global Interleukin Inhibitors Market historical market size for years: 2019, 2020, 2021, 2022 and 2023. The report also forecasts the Global Interleukin Inhibitors Market size for years: 2024, 2025, 2026, 2027, 2028 and 2029.
Global Interleukin Inhibitors Industry Report
Statistics for the 2024 Global Interleukin Inhibitors market share, size and revenue growth rate, created by Mordor Intelligence™ Industry Reports. Global Interleukin Inhibitors analysis includes a market forecast outlook to 2029 and historical overview. Get a sample of this industry analysis as a free report PDF download.
